Artificial Organs Market

Artificial Organs Market Size:

The global artificial organs market size reached USD 22.2 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 44.5 Billion by 2033, exhibiting a growth rate (CAGR) of 7.22% during 2025-2033. The market is experiencing steady growth driven by the increasing need for 3D bioprinting due to its capability to minimize the risk of organ rejection, rising prevalence of chronic diseases, such as cancer, diabetes, hypertension, stroke, heart disease, and respiratory diseases, and the escalating demand for organ transplantation.

Artificial Organs Market Analysis:

• Market Growth and Size: The market is witnessing moderate growth, driven by the increasing awareness among the masses about organ donation and transplantation. Moreover, the rising geriatric population is propelling the growth of the market. 
• Technological Advancements: Innovations in bioartificial organ manufacturing technologies are enabling the production of human organs based on bionic principles. Additionally, the increasing utilization of combined multi-nozzle three-dimensional printing techniques to automatically assemble personal cells, along with other biomaterials to build exclusive organ substitutes for defective/failed human organs, is impelling the market growth.
• Industry Applications: Artificial organs are utilized to model almost all organs in humans for drug testing, disease modeling, and personalized medicine. They are also used as an alternative to renal replacement for treating end stage renal disease patients.
• Geographical Trends: North America leads the market, on account of the increasing number of transplant surgeries. However, Europe is emerging as a fast-growing market, driven by the growing incidences of heart disease and end-stage kidney and lung disorders.
• Competitive Landscape: The market is characterized by the presence of many large, small, and medium-scale key players. These players are focusing on developing innovative products and regional expansion to gain maximum revenue share in the industry. Mergers and acquisitions (M&A) are supporting them to expand their existing product portfolio and increase their geographical footprints.
• Challenges and Opportunities: While the market faces challenges, such as vascularization, the growth of blood vessels, as it requires effective transport of oxygen, nutrients, and removal of cell-secreted waste for the survival of cells, it also encounters opportunities in the growing need for kidney substitute, hemodialysis, cardiopulmonary bypass (CPB), apheresis therapy, peritoneal dialysis, lung substitute and assist, and plasma separation.
• Future Outlook: The future of the artificial organs market looks promising, with advancements in biomaterials, innovations in processing technologies, development of highly durable devices, and progresses in decellularization of animal tissue and organs and cell-based therapies.
   

Artificial Organs Market Trends:

Advancements in 3D bioprinting

Innovations in the field of 3D bioprinting are crucial in organ transplanting as it is used for developing artificial organs. 3D bioprinting is gaining traction due to its capability to minimize the risk of organ rejection. In addition, the integration of artificial intelligence (AI) in artificial organs is transforming the global trends for artificial devices. Moreover, many countries are focusing on a tool that provides a customized assessment of organ and donor suitability. This tool can be very helpful in making effective decisions about organ retrieval while assisting patients in deciding if they should accept donor organs or wait for better options. Furthermore, the growing focus on bioprinting organs and tissues, recellularization strategies, cellular repair or regeneration, and new functional biomaterials for the next generation of devices is offering a favorable market outlook. In line with this, the development of bioreactors to provide adequate oxygenation and guarantee transport of nutrients to, and metabolic products from, the tissue is bolstering the artificial organs market growth.

Increasing prevalence of chronic diseases

The rising occurrence of chronic diseases, such as cancer, diabetes, hypertension, stroke, heart disease, respiratory diseases, arthritis, obesity, and oral diseases, is catalyzing the demand for artificial organs. They provide a solution to patients who are suffering from organ failure or functional limitations. As chronic diseases eventually lead to organ failure, there is a rise in the demand for artificial organs, however, the supply of organ donors is limited. As a result, artificial organs and bionic plants are used as an alternative that provides life-saving treatments while reducing dependency on organ donors. Moreover, the increasing demand for artificial hearts on account of the rising prevalence of cardiovascular diseases to replace damaged heart ventricles and valves is offering lucrative growth opportunities to industry investors. Artificial hearts have ventricles made from polyurethane, a widely used artificial material that is both durable and flexible, which makes it highly dependable.

Rising demand for organ transplantation

The growing demand for organ transplantation due to the increasing number of people with end-stage organ failure around the world is offering a favorable market outlook. Additionally, the rising demand for renal transplantation over dialysis, along with the escalating demand for lifesaving transplants to treat patients with liver, heart, or lung irreversible diseases, is strengthening the growth of the market. Moreover, organ transplantation is considered as the best therapy for terminal and irreversible organ failure. In addition, the introduction of cyclosporine to improve transplant outcomes, coupled with the growing number of solid organ transplant programs across the globe, is positively influencing the market. Furthermore, the implementation of transplant programs assists in encouraging people for organ donation and defining the optimization of transplant clinical practices and an economic effort by the distinct health care systems. These programs aim to improve the life expectancy, clinical condition, and quality of life of solid organ transplant recipients.

Artificial Organs Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global and regional levels for 2025-2033. Our report has categorized the market based on the type.

Breakup by Type:

• Artificial Kidney
• Artificial Heart
• Artificial Pancreas
• Cochlear Implants
• Others
   

Artificial kidney accounts for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the type. This includes artificial kidney, artificial heart, artificial pancreas, cochlear implants, and others. According to the report, artificial kidney represents the largest segment due to the increasing number of patients needing renal replacement therapy (RRT). Moreover, the growing number of lifestyle diseases, such as diabetes, hypertension, and metabolic syndrome, is catalyzing the demand for artificial kidneys. Kidney transplantation, whenever feasible, is the most preferred mode of RRT. As a result, there is a rise in the demand for artificial kidney that can be wearable or implantable and can perform the complete excretory, filtration, tubular, endocrine, and metabolic functions of the kidney while preserving the quality of life and minimizing complications.

Artificial heart is a device that maintains blood circulation and oxygenation in the human body for an extended period. It can be used by people having conditions, such as an uncontrollable ventricular arrhythmia, end-stage complications of congenital heart defects, ventricles that are not the right shape for a ventricular assist device (VAD), broken or ruptured ventricles, a left ventricle that fails to work properly after a mechanical valve replacement surgery, and blood clots in the lining of the blood vessels and heart. It is highly beneficial for heart patients, as it is made from material that the body typically does not reject.

An artificial pancreas is made of three parts that work together to mimic how a healthy pancreas controls blood glucose level in the body. It is mainly used to help people with type 1 diabetes. It relies on a continuous glucose monitor (CGM) that tracks blood glucose levels every few minutes using a tiny sensor that is inserted under the skin. The sensor wirelessly sends the information to a program stored on a smartphone or on an insulin infusion pump. The insulin infusion pump delivers small doses of insulin throughout the day when blood glucose levels are not in the target range.

Cochlear implants are small electronic devices that allow people to hear sounds. They can help people to understand speech with less reliance on lip reading and to perceive sounds. They directly stimulate the part of the ear that does not work by using a mild electrical current applied to the structures in the cochlea.

Breakup by Region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa
   

North America leads the market, accounting for the largest artificial organs market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America, Europe, Asia Pacific, the Middle East and Africa, and Latin America. According to the report, North America accounts for the largest market share on account of the increasing number of transplant surgeries. Moreover, the growing need for artificial organs due to the high incidence of organ failure is offering a favorable market outlook. In addition, the presence of well-developed healthcare facilities and the local presence of many large biotechnology and medical device companies are propelling the growth of the market. Besides this, the increasing number of donors, along with the rising demand for kidney transplantation in the region, is bolstering the growth of the market.

The growing aging population in Europe is offering a favorable market outlook. An aging population results in an increasing prevalence of chronic diseases and age-related organ failure, catalyzing the demand for artificial organs to address the healthcare needs of this demographic. Moreover, the growing burden of heart disease and end-stage kidney and lung disorders is positively influencing the market. Apart from this, the rising demand for medical bionic implants and artificial organs due to the increasing use of bionic prosthetic devices is bolstering the growth of the market in the region.

Asia-Pacific is expected to grow at a significant rate due to a large consumer base, rising government initiatives for enhancing healthcare, and high disposable income. Additionally, the increasing awareness among the masses about the benefits of organ transplantation is supporting the growth of the market. Besides this, governing agencies in the region are promoting domestic medical devices at a high level of legitimacy in the global context, allowing key players to expand their overseas footprint, attract international talent, and scale up clinical research programs.

With a rise in chronic diseases, including cardiovascular diseases, diabetes, and kidney disorders, there is a rise in the demand for artificial organs in the Middle East and Africa region. Artificial organs, such as artificial hearts and pancreas, offer patients a chance at a better quality of life and extended longevity. Moreover, the shortage of viable organs for transplantation is a concern in the region. Artificial organs serve as a bridge to transplantation, providing patients with critical support until a suitable donor organ becomes available. Furthermore, advancements in materials science, miniaturization, and biotechnology are impelling the growth of the market.

The growing incidence of organ failure due to blood loss, drug addiction, severe trauma, poor sanitation habits, and genetic deformities is positively influencing the market in the Latin America region. Additionally, lifestyle disorders like poor eating habits, smoking, alcohol consumption, stress, and lack of exercise are propelling the market growth in the region.

Leading Key Players in the Artificial Organs Industry:

The artificial organs market is highly fragmented with the presence of many large, small, and medium-scale vendors. In addition, key players are focusing on developing innovative products and regional expansion to gain maximum revenue share in the industry. Mergers and acquisitions (M&A) are supporting them to expand their existing product portfolio and increase their geographical footprints. Moreover, key manufacturers are evolving advanced artificial intelligence (AI) design that can recognize patients who are expected to have a lesser gait speed outcome, after hip or knee surgical intervention. They are also introducing robotic technologies digitally designed to offer transformative data-powered clinical insights to boost patient outcomes, with strong predictive analytic capabilities. Furthermore, key players are focusing on the demonstration of a functional prototype of their implantable artificial kidneys, which is expected to positively influence the artificial organs market scope.

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

• Abiomed, Inc.
• HeartWare International, Inc.
• Edwards Lifesciences Corp
• Boston Scientific Corporation
• Cochlear Limited
   

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

Latest News:

• March 31, 2022: Edwards Lifesciences Corp announced that it has received approval from the U.S. Food and Drug Administration (FDA) for the MITRIS RESILIA valve, a tissue valve replacement specifically designed for the mitral position of the heart. The MITRIS RESILIA valve has a saddle-shaped sewing cuff that mimics the asymmetric shape of the native mitral valve. It also features a low-profile frame that helps avoid obstruction of the left ventricular outflow tract by stent posts and is visible under fluoroscopy, to facilitate potential future transcatheter interventions for patients.
• January 10, 2022: Cochlear Limited announced that the FDA has approved an expansion of the Cochlear™ Nucleus® System indications to include Single Sided Deafness and Unilateral Hearing Loss (SSD/UHL) for individuals 5 years and older. This can help more people hear by removing barriers to accessing implantable hearing solutions.
   

Artificial Organs Market Report Scope:

Key Benefits for Stakeholders:

• IMARC’s industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the artificial organs market from 2019-2033.
• The research report provides the latest information on the market drivers, challenges, and opportunities in the global artificial organs market.
• The study maps the leading, as well as the fastest-growing, regional markets.
• Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the artificial organs industry and its attractiveness.
• The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.